Croatian guidelines for diagnostics and treatments of helicobacter pylori infection;Hrvatski postupnik za dijagnostiku i terapiju infekcije helicobacterom pylori

Lijecnicki Vjesnik

Volumn 136, Issue 1-2, 2014, Pages 1-17

  Katičić, Miroslava ^a   Duvnjak, Marko ^b   Kanižaj, Tajana Filipec ^a   Krznarić, Željko ^f   Marušić, Marinko ^e   Mihaljević, Silvijo ^d   Plećko, Vanda ^g   Pulanić, Roland ^f   Šimunić, Miroslav ^c   Tonkić, Ante ^c  

^a University of Zagreb   (Croatia)

^b SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^c UNIVERSITY OF SPLIT   (Croatia)

^d JOSIP JURAJ STROSSMAYER UNIVERSITY OF OSIJEK   (Croatia)

^e Hrvatsko Gastroenterolo ko Dru tvo Klini ka Bolnica Sveti Duh   (Croatia)

^f UNIVERSITY OF ZAGREB   (Croatia)

^g KBC Zagreb   (Croatia)

Author keywords

Algorithms; Anti bacterial agents therapeutic use; Bismuth therapeutic use; Croatia; Drug therapy, combination; Helicobacter infections diagnosis, drug therapy, complications; Helicobacter pylori isolation and purifications, pathogenicity, drug effects; Proton pump inhibitors therapeutic use

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; ANTIULCER AGENT;

CONSENSUS DEVELOPMENT; CROATIA; HEALTH CARE QUALITY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMAN; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; STANDARDS;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; CROATIA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; QUALITY OF HEALTH CARE;

EID: 84896961321     PISSN: 00243477     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (148)

1. Warren Jr. Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983, str. 1273-1275.
2. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994;61: 1-241.
3. Correa P, Houghton J. Carcinogenesis of Helicobacter pylori. Gastroenterology 2007;133:659-72.
4. Babuš V, Presečki V, Katičič M i sur. Rasprostranjenost infekcije s Helicobacter pylori u odrasloj populaciji Hrvatske. Liječ Vjesn 1997; 119: 139-142.
5. Malfertheiner P, Megraud F, O'Morain C i sur. Current European concepts in the management of Helicobacter pylori infection - the Maastricht Consensus Report. The European Helicobacter pylori study group (EHPSG). Eur J Gastroenterol Hepatol 1997;9:1-2.
6. Malfertheiner P, Megraud F, O'Morain C i sur. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16:167-70.
7. Malfertheiner P. Megraud F. O'Morain C i sur. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-81.
8. Malfertheiner P, Megraud F, O'Morain C i sur. Management of Helicobacter pylori infection the Maastricht IV/Florence Consensus Report. Gut 2012;61:646-64.
9. Wolfe MM, Soil AH. The physiology of gastric acid secretion. N Engl J Med 1988;319:1707-15.
10. LeodolterA, Kulig M, Brasch H i sur. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther 2001; 15: 1949-58.
11. Malfertheiner P. Bayerdorffer E, Diete U i sur. The GU-M ACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther 1999; 13:703-12.
12. LabenzJ, Tillenburg B, Peitz U i sur. Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients. Am J Gastroenterol 1997;92:576-81.
13. GisbertJP, KhorramiS, Carballo F i sur. H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. The Cochrane Database of Systematic Reviews, 2004; Issue 2, Art. No. CD004062.pub2.
14. Isaacson PG, Chott A, Nakamura S i sur. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). U: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008, str. 214-217.
15. Zullo A, Hassan C, Cristofari F i sur. Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol 2010;8:105-10.
16. Wotherspoon AC, Doglioni C, Diss TC i sur. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993;342: 575-7.
17. Savio A, Franzin G, Wotherspoon AC i sur. Diagnosis and posttreatment follow-up of Helicobacter pvlori-positive gastric lymphoma of muco- sa-associated lymphoid tissue: histology, polymerase chain reaction, or both? Blood 1996;87:1255-60.
18. Liu H, Ye H, Ruskone-Fourmestraux A i sur. T (11; 18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology 2002; 122:1286-94.
19. Liu H, Ruskone-Fourmestraux A, Lavergne-Slove A i sur. Resistance of t(ll;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 2001;357(9249): 39-40.
20. Ruskone-Fourmestraux A, Lavergne A, Aegerter PH i sur. Predictive factors for regression of gastric MALT lymphoma after anti-Helico-bacter pylori treatment. Gut 2001;48:297-303.
21. Correa P. A human model of gastric carcinogenesis. Cancer Res 1988; 48:3554-60.
22. Wong BC, Lam SK, Wong WM i sur. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187-94.
23. Correa P, Fontham ET, Bravo JC i sur. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Heli-cobacter pylori therapy. J Natl Cancer Inst 2000;92:1881-8.
24. Leung WK, Lin SR. Ching JY i sur. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 2004;53:1244-9.
25. Wang J, Xu L, Shi R, HuangX i sur. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion 2011;83:253-60.
26. Cassaro M, Rugge M, Gutierrez O i sur. Topographic patterns of intestinal metaplasia and gastric cancer. Am J Gastroenterol 2000;95: 1431-38.
27. Vannella L, Lahner E, Osborn J i sur. Risk factors for progression to gastric neoplastic lesions in patients with atrophic gastritis. Aliment Pharmacol Ther 2010;31:1042-50.
28. Maruta F, Sugiyama A, lshizone S i sur. Eradication of Helicobacter pylori decreases mucosal alterations linked to gastric carcinogenesis in Mongolian gerbils. J Gastroenterol 2005;40:104-5.
29. El-Serag HB, Talley NJ. Systemic review: the prevalence and clinical course of functional dyspepsia. Aliment Pharmacol Ther 2004; 19: 643-54.
30. Tucci A, Corinaldesi R, Stanghellini V i sur. Helicobacter pylori infection and gastric function in patients with chronic idiopathic dyspepsia. Gastroenterology 1992;103:768-74.
31. Saslow SB, Thumshirn M, Camilleri i sur. Influence of H pylori infection on gastric motor and sensory function in asymptomatic volunteers. Dig Dis Sci 1998;43:258-64.
32. Mearin F, de Ribot X, Balboa A i sur. Does Helicobacter pylori infection increase gastric sensitivity in functional dyspepsia? Gut 1995;37:47.
33. Chiba N, Van Zanten SJ, Sinclair P i sur. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial. Br Med J 2002;324: 1012-16.
34. Moayyedi P, Deeks J, Talley NJ i sur. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol 2003;98:2621-6.
35. Moayyedi P, Walson C, Peacock R i sur. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter 2000;5:206-14.
36. El-Omar EM, Oien K, Rl-Nujumi A i sur. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997;113: 15-24.
37. Mihaljević S, Katičić M, Krznarić Ž i sur. The influence of the different morphological changes on gastric mucosa on somatostatin cell number in antrum mucosa and serum somatostatin. Coll Antropol 2011;35: 5-8.
38. Cullen D, Hawkey G, Greenwood D i sur. H. pylori and gastroesophageal reflux disease: a community-based study. Helicobacter 2008;13: 352-60.
39. O'Connor HJ. Review article: Helicobacter pylori and gastro-oesopha-geal reflux disease-clinical implications and management. Aliment Pharmacol Ther 1999; 13:117-27.
40. Rokkas T, Pistiolas D, Sechopoulos P i sur. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol 2007;5:1413-17.
41. Yaghoobi M, Farrokhyar F, Yuan Y i sur. Is there an increased rise of GERD after Helicobacter pylori eradication?: a meta-analysis. Am J Gastroenterol 2010;105:107-13.
42. Quian B, Shije M, Shang L i sur. Effect of H. pylori eradication on gastroesophageal reflux disease. Helicobacter 2011; 16:255-65.
43. Lundell L, Havu N, Miettinen P i sur. Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomised clinical trial. Aliment Pharmacol Ther 2006;23:639-47.
44. Fox JG, Kuipers EJ. Long-term proton pump inhibitor administration. H. pylori and gastric cancer: lessons from the gerbil. Gut 2011;60: 567-8.
45. Kiltz U, ZochlingJ, Schmidt WE, Braun J. Use of NSAIDs and infection with Helicobacter pylori - what does the rheumatologist need to know? Rheumatology 2008;47:1342-47.
46. Vergara M, Catalan M, Gisbert JP, Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005;21:1411-8.
47. de Leest HT, Steen KS, Lems WF i sur. Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment: double-blind, randomized, placebo-controlled trial. Helicobacter 2007; 12:477-85.
48. Qu XH, Huang XL, Xiong P i sur. Does Helicobacter pylori infection play a role in iron deficiency anemia? A meta-analysis. World J Gastroenterol 2010;16:886-96.
49. Muhsen K, Cohen D. Helicobacter pylori infection and iron stores: a systematic review and meta-analysis. Helicobacter 2008;13:323-40.
50. Malik R, Guleria K, Kaur I, Sikka M, Radhakrishnan G. Effect of Helicobacter pylori eradication therapy in iron deficiency anaemia of pregnancy - a pilot study. Ind J Med Res 2011;134:224-31.
51. Franchini M, Veneri D. Helicobacter pylori and immune thrombocytopenic purpura. Haematologica 2003;88:1087-93.
52. British society for hematology. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003;120:574-96.
53. Takahashi T, Yujiri T, Shinohara K i sur. Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori - associated chronic idiopathic thrombocytopenic purpura. Br J Hematol 2004;124:91-6.
54. Saito A, Yokohama A, Osaki Y i sur. Circulating plasmacytoid dendritic cells in patients with primary and Helicobacter pylori-associated immune thrombocytopenia. Eur J Haematol 2012;88:340-9.
55. Serin E, Gümürdülü Y, Ozer B i sur. Impact of Helicobacter pylori on the development of vitamin B12 deficiency in the absence of gastric atrophy. Helicobacter 2002;7:337-41.
56. Bugdaci MS, Zuhur SS, Sokmen M i sur. The role of Helicobacter pylori in patients with hypothyroidism in whom could not be achieved normal thyrotropin levels despite threatment with high doses of thyroxine. Helicobacter 2011; 16:124-30.
57. Katičić M, Presečki V, Kalenić S i sur. Diagnosis of Helicobacter pylori infection. Liječ Vjesn 2002;124(Suppl 1): 16-20.
58. Filipec T, Katičić M, Papa B i sur. Ureja izdisajni test. Liječ Vjesn 2002;124(Suppl l):28-33.
59. Stenstrom B, Mendis A, Marshall B. Helicobacter pylori - The latest in diagnosis and treatment. Aust Fam Phys 2008;37:608-12.
60. Moayyedi P, Axon AT. The usefulness of the likelihood ratio in the diagnosis of dyspepsia and gastroesophageal reflux disease. Am J Gastroenterol 1999;94:3122-5.
61. Niv Y, Niv G, Koren R. 13C-urea breath test for diagnosis of Helicobacter pylori infection in the elderly. Dig Dis Sci 2004;49:1840-4.
62. Ikenberry SO, Harrison ME, Lichtenstein D i sur. The role of endoscopy in dyspepsia. Gastrointest Endosc 2007;66:1071-5.
63. Gisbert JP, Pajares JM. Review article: 13C-urea breath test in the diagnosis of Helicobacter pylori infection - a critical review. Aliment Pharmacol Ther 2004;20:1001-17.
64. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998;93: 2330-8.
65. Vaira D, Holton J, Menegatti M i sur. Review article: invasive and noninvasive tests for Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14(Suppl 3): 13-22.
66. Nocon M, Kuhlmann A, Leodolter A, Roll S, Vauth C, Willich SN, Greiner W. Efficacy and cost-effectiveness of the 13C-urea breath test as the primary diagnostic investigation for the detection of Helicobacter pylori infection compared to invasive and non-invasive diagnostic tests. GMS Health Technol Assess 2009;5:Docl4.
67. Gatta L, Vakil N, Ricci C i sur. Effect of proton pump inhibitors and antacid therapy on 13C urea breath tests and stool test for Helicobacter pylori infection. Am J Gastroenterol 2004;99:823-9.
68. Gisbert JP, de la Morena F, Abraira V. Accuracy of monoclonal stool antigen test for the diagnosis of H, pylori infection: a systematic review and meta-analysis. Am J Gastroenterol 2006;101:1921-30.
69. Calvet X, Lario S, Ramirez-Lazaro MJ i sur. Accuracy of monoclonal stool tests for determining cure of Helicobacter pylori infection after treatment. Helicobacter 2010;15:201-5.
70. Vaira D, Vakil N, Menegatti M i sur. The stool antigen test for detection of Helicobacter pylori after eradication therapy. Ann Intern Med 2002; 136:280-7.
71. Feldman RA, Deeks JJ, Evans SJ. Multi-laboratory comparison of eight commercially available Helicobacter pylori serology kits. Helicobacter pylori Serology Study Group. Eur J Clin Microbiol Infect Dis 1995; 14:428-33.
72. Fauchere RA, Charlier-Bret N, Courillon-Mallet A i sur. Evaluation comparative de 29 trousses commercialises pour le diagnostic se- rologique de l'infection par Helicobacter pylori: etude multicentrique du Groupe d'etude Francais des Helicobacters (GEFH). Feuillet de Bio-logie 2011;298:25-32.
73. Feldman M, Cryer B, Lee E, Peterson WL. Role of seroconversion in confirming cure of Helicobacter pylori infection. JAMA 1998;280: 363-5.
74. Marušić M, Presečki V, Katičić M, Dominis M, Kalenić S. The place and role of serologic methods in detecting Helicobacter pylori infection. Coll Antropol 2006;30:529-33.
75. Lehours P, Ruskone-Fourmestraux A, Lavergne A i sur. Which test to use to detect Helicobacter pylori infection in patients with low-grade gastric mucosa-associated lymphoid tissue lymphoma? Am J Gastroenterol 2003;98:291-5.
76. Kokkola A, Rautelin H, Puolakkainen P i sur. Diagnosis of Helicobacter pylori infection in patients with atrophic gastritis: comparison of histology, 13C-urea breath test, and serology. Scand J Gastroenterol 2000;35:138-41.
77. Gisbert JP, Esteban C, Jimenez I i sur. 13C-urea breath test during hospitalization for the diagnosis of Helicobacter pylori infection in peptic ulcer bleeding. Helicobacter 2007; 12:231-7.
78. Barkun AN, Bardou M, Kuipers EJ i sur. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2010;152:101-13.
79. Satoh K, Kimura K i sur. A follow-up study of atrophic gastritis and intestinal metaplasia after eradication of Helicobacter pylori. Helicobacter 1998;3:236-40.
80. Price AB. The Sydney system: histological division. J Gastroenterol Hepatol 1991;6:209-22.
81. Stolte M, Meining A. The updated Sydney system: classification and grading of gastritis as the basis of diagnosis and treatment. Can J Gastroenterol 2001;9:591-8.
82. Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006;19:449-90.
83. Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology 2008;134:1842-60.
84. Logan RP, Walker MM, Misiewitz JJ i sur. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 1995;36:12-6.
85. Stolte M, Stadelmann O, Bethke B, Burkhard G. Relationship between the degree of Helicobacter pylori colonisation and the degree and activity gastritis, surface epithelial degeneration and mucus secretion. Z Gastroenterol 1995;33:89-93.
86. Yakoob J, Jafri W, Abid S i sur. Role of rapid urease test and histopatho-logy in the diagnosis of Helicobacter pylori infection in a developing country. BMC Gastroenterol 2005;1:38-42.
87. van der Hulst RWM, Verheul SB, Weel JF i sur. Effect of specimen collection techniques, transport media, and incubation of cultures on the detection rate of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1996;15:211-5.
88. Audibert C, Janvier B, Grignon B i sur. Correlation between IL-8 induction, cagA status and vacA genotypes in 153 French Helicobacter pylori isolates. Res Microbiol 2000;151:191-200.
89. Megraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007;20:280-322.
90. Thoreson ACE, Borre M, Andersen LP i sur. Helicobacter pylori detection in human biopsies: a competitive PCR assay with internal control reveals false results. FEMS Immunol Med Microbiol 1999;24:201-8.
91. De Francesco V, Zullo A, lerardi E i sur. Phenotypic and genotypic Helicobacter pylori clarithromycin resistance and therapeutic outcome: benefits and limits. J Antimicrob Chemother 2010;65:327-32.
92. Levine A, Shevah O, Shabat-Sehayek V i sur. Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole. Aliment Pharmacol Ther 2004;20:117-22.
93. Ozturk E, Yesilova Z, Ilgan S i sur. Performance of acidified 14C-urea capsule breath test during pantoprazole and ranitidine treatment. J Gastroenterol Hepatol 2009;24:1248-51.
94. Erzin Y, Altun S, Dobrucali A i sur. Evaluation of two enzyme immunoassays for detecting Helicobacter pylori in stool specimens of dyspeptic patients after eradication therapy. J Med Microbiol 2005;54:863-6.
95. Asfeldt AM, Lochen ML, Straume B i sur. Accuracy of a monoclonal antibody-based stool antigen test in the diagnosis of Helicobacter pylori infection. Scand J Gastroenterol 2004;39:1073-7.
96. Graham DY, Opekun AR, Hammoud F i sur. Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors. Am J Gastroenterol 2003;98:1005-9.
97. Gisbert JP, Pajares JM. 13C-urea breath test in the management of Helicobacter pylori infection. Dig Liver Dis 2005;37:899-906.
98. Graham DY, Opekun AR, Jogi M i sur. False negative urea breath tests with H2-receptor antagonists: interactions between Helicobacter pylori density and pH. Helicobacter 2004;9:17-27.
99. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59:1143-53.
100. Glupczynski Y, Megraud F, Lopez-Brea M i sur. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001;20:820-3.
101. Megraud F, Coenen S, Versporten A i sur. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption, Gut 2012; 62:34-42.
102. Plećko V, Katičić M, VardaBrkić D, Tripković V, Starčević L. Primary resistance of Helicobacter pylori to macrolides and metronidazole in the northern part of Croatia. Helicobacter 2012; 17(Suppl. 1):107.
103. Gisbert JP, Calvet X, O'Connor A isur. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 2010; 44:313-25.
104. Vaira D, Zullo A, Vakil N i sur. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007;146:556-63.
105. Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther 2011;34:604-17.
106. Treiber G, Ammon S, Schneider E, Klotz U. Amoxicillin/metronidazole/ omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. Helicobacter 1998;3:54-58.
107. Essa AS, Kramer JR, Graham DY i sur. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing concomitant therapy versus triple therapy for Helicobacter pylori eradication. Helicobacter 2009;14:109-18.
108. Gisbert JP, Fernandez-Bermejo M, Molina-Infante J i sur. First-line triple therapy with levofloxacin for Helicobacter pylori eradication. Aliment Pharmacol Ther 2007;26:495-500.
109. Gisbert JP, de la Morena F. Systematic review and meta-analysis:le- vofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006;23:35-44.
110. Saad RJ, Schoenfeld P, Hyungjin K, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta analysis. Am J of Gastroenterol 2006;101:488-96.
111. Borody TJ, Carrick J, Hazell SL. Symptoms improve after the eradication of gastric Campylobacter pylori. Med JAust 1987;146:450-51.
112. Megraud F. The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy. Therap Adv Gastroenterol 2012;5:103-9.
113. Tonkić A, Tonkić M, Brnić D, Novak A, Puljiz Z, Šimunić M. Times trend of primary antibiotic resistance of Helicobacter pylori isolates in Southern Croatia. J Chemother 2012;24:182-4.
114. Laine L, Hunt R, El-Zimaity H i sur. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole and tetracycline given with omeprazole versus omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003;98:562-7.
115. Malfertheiner P, Bazzoli F, Delchier JC i sur. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole and tetracycline given with omeprazole versus clari-thromycin- based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011;377:905-13.
116. Jalalzadeh M, Nazarian M, Vafaeimanesh J, Mirzamohammadi F. Comparison of azithromycin and clarithromycin triple therapy regimens for Helicobacter pylori eradication in hemodialysis patients. Nephro-Urology Monthly 2012;4:571-7.
117. Dong J, YuXF, ZouJ. Azithromycin-containing versus standard triple therapy for Helicobacter pylori eradication: a meta analysis. World J Gastroenterol 2009;15:6102-6110.
118. Gisbert JP, Gonzalez L, Calvet X i sur. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther 2000; 14:1319-28.
119. Filipec Kanilaj T, Katičić M, Škurla B i sur. Helicobacter pylori eradication therapy success regarding different treatment period based on clarithromycin or metronidazole triple-therapy regimens. Helicobacter 2009; 14:29-35.
120. Fuccio L, Minardi ME, Zagari RM i sur. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007;147:553-62.
121. Villoria A. Acid-related diseases: are higher doses of proton pump inhibitors more effective in the treatment of Helicobacter pylori infection? Gastroenterol Hepatol 2008;31:546-7.
122. SachdevaA, Nagpal J. Meta-analysis: efficacy of bovine lactoferrin in Helicobacter pylori eradication. Aliment Pharmacol Ther 2009;29: 720-30.
123. Huynh HQ, Campbell MA, Couper RT, Tran CD, Lawrence A, Butler RN. Lactoferrin and desferoxamine are ineffective in the treatment of Helicobacter pylori infection and may enhance H. pylori growth and gastric inflammation in mice. Lett Appl Microbiol 2009;48: 517-22.
124. TongJL, Ran ZH, ShenJ, Zhang CX i sur. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007;25:155-68.
125. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010;32:1069-79.
126. Rokkas T, Sechopoulos P, Robotis I i sur. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht HI consensus and a third-line empirical regimen. Am J Gastroenterol 2009;104:21-5.
127. Gisbert JP, Gisbert JL, Marcos S i sur. Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients. Aliment Pharmacol Ther 2008;27:346-54.
128. KatičićM, Filipec Kanižaj T, Mrzljak A i sur. Time trends in the choice of H. pylori rescue treatments after one or two failures of standard PPT - clarithromycin/metronidazole containing therapy in Referral Centre for H. pylori in Zagreb, Croatia. Helicobacter 2012; 17(Suppl. 1) :74.
129. Gisbert JP, Gisbert JL, Marcos S i sur. Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. Aliment Pharmacol Ther 2005;22:1041-6.
130. Rodriguez-Torres M, Salgado-Mercado R, Rios-Bedoya CF i sur. High eradication rates of Helicobacter pylori infection with first- and second - line combination of esomeprazole, tetracyclin and metronidazole in patients allergic to penicillin. Dig Dis Sci 2005;50:634-9.
131. Leodolter A, Kulig M, Brasch H i sur. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther 2001;15:1949-58.
132. Gisbert JP, PajaresJM. Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer? Aliment Pharmacol Ther 2005;21:795-804.
133. ArkkilaPE, Seppala K, Kosunen TU i sur. Helicobacter pylori eradication as the sole treatment for gastric and duodenal ulcers. Eur J Gastroenterol Hepatol 2005;17:93-101.
134. Gisbert JP. The recurrence of Helicobacter pylori infection: incidence and variables influencing it. A critical review. Am J Gastroenterol 2005;100:2083-99.
135. Moayyedi P. The health economics of Helicobacter pylori infection. Best Pract Res Clin Gastroenterol 2007;21:347-61.
136. Ford AC, Delaney BC, Forman D i sur. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004;99:1833-55.
137. Huang JQ, Sridhar S, Hunt RH Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta analysis. Lancet 2002;359:14-22.
138. Chan FK, To KF, Wu JC i sur. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with nonsteroidal anti-inflammatory drugs: a randomised trial. Lancet 2002: 359:9-13.
139. Vergara M, Catalan M, Gisbert JP i sur. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005;21:1411-18.
140. Chan FK, Chung SC, Suen BY i sur. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344:967-73.
141. Malfertheiner P, Sipponen P, Nutnann M i sur. Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the - art critique. Am J Gastroenterol 2005;100:2100-15.
142. Kodama M, Murakami K, Okimoto T i sur. Helicobacter pylori eradication improves gastric atrophy and intestinal metaplasia in long-term observation. Digestion 2012;85:126-30.
143. Wundisch T, Thiede C, Morgner A i sur. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 2005;23:8018-24.
144. Megraud F. Helicobacter pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53:1374-84.
145. Ferech M, Coenen S, Malhotra-Kumar S i sur. European surveillance of antimicrobial consumption (ESAC): outpatient antibiotic use in Europe. J Antimicrob Chemother 2006;58:401-7.
146. Coenen S, Ferech M, Malhotra-Kumar S, Hendrix E, Suetens C, Grossens H. European surveillance of antimicrobial consumption (ESAC): outpatient macrolide, lincosamide and streptogramin (MILS) use in Europe. J Antimicrob Chemother 2006;58:418-22.
147. TonkićA, Tonkić M, Lehours P, MegraudF. Epidemiology and diagnosis of Helicobacter infection. Helicobacter 2012;17:1-8.
148. Romano M, Marmo R, Cuomo A i sur. Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori. Clin Gastroenterol Hepatol 2003;1:273-8.